These Analysts Raise Their Forecasts On Regeneron Pharmaceuticals After Upbeat Q3 Results
Regeneron beat Q3 estimates with EPS up 70% and revenue up 36%; analysts raised price targets to as high as $1,175.
Share
Why It Matters
Regeneron made way more money than experts expected this quarter. When a company does really well, smart analysts think its stock might go higher.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.